Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

ESSA Pharma Inc. Director's Dealing 2021

Jan 11, 2021

35249_dirs_2021-01-11_ac7eb22a-600f-4522-b900-fb29529fd6c3.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: ESSA Pharma Inc. (EPIX)
CIK: 0001633932
Period of Report: 2020-12-11

Reporting Person: Virsik Peter (Chief Operating Officer)

Derivative Transactions

Date Security Exercise Price Code Shares A/D Expiration Underlying Ownership
2020-12-11 Stock Option (Right to Buy) $7.00 A 200000 Acquired 2030-12-11 Common Shares (200000) Direct

Footnotes

F1: 25% of the options vest after 12 months from the date of grant, and the remaining 75% vest in 36 equal installments with the first installment vesting at the end of the 13th month and subsequent installments vesting on every one month anniversary thereafter.